Brief: Imagion Biosystems Files IND To FDA For Phase 2 Trial Of Magsense Her2 Targeted Imaging Agent
03/02/2026 17:27
Feb 3 (Reuters) - Imagion Biosystems Ltd IBX.AX: MEDICAL-IMAGING COMPANY IMAGION BIOSYSTEMS LODGES IND WITH FDA FOR PHASE 2 TRIAL OF MAGSENSE® HER2 TARGETED IMAGING AGENT IMAGION BIOSYSTEMS LTD - ENROLLMENT FOR PHASE 2 TRIAL COULD BEGIN Q1 2026 ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imagion Biosystems
See all newsBrief: Imagion Biosystems Resumes Magsense Nanoparticle Manufacturing Capabilities
Brief: Imagion Biosystems Secures AU$3.75M In Capital Raise Following FDA Clearance Of Phase 2 Clinical Trial
Brief: Imagion Biosystems Secures A$3.75 Million In Firm Commitments Under Capital Raising
Australia's Imagion Biosystems falls on discounted placement
Brief: Imagion Biosystems Seeks Trading Halt